Led by Jeremy Rich, M.D., associate professor at the Preston Robert Tisch Brain Tumor Center at Duke University, the researchers found that a small subset of glioma cells expressed higher levels of a growth factor associated with cancer cell growth. They believe this subset could be a target for new therapies against these intractable brain tumors.
Gliomas are the most common type of brain tumor, making up about half of all diagnosed primary (or non-metastatic) brain tumors. About 17,000 people in the United States are diagnosed with a primary brain tumor each year. Patients with the most aggressive glioma, called glioblastoma, have an average life expectancy of less than one year despite advances in cancer treatment. To better treat cancer patients, laboratories like those of Rich are trying to better understand the causes of tumor growth so that gliomas can be targeted with new drugs.
"Malignant brain tumors are highly lethal, despite aggressive surgery, radiation, and chemotherapy," said Dr. Rich. "We believe targeting the cancer stem cells of brain tumors may offer a novel therapy that will help to decrease the blood supply feeding a growing tumor, and therefore decrease or stop that tumor's growth."
Researchers from other laboratories recently determined that a small fraction of all the cells in a glioma have special characteristics similar to brain stem cells. These stem cell-like glioma cells form tumors when implanted in animals. As the ability to form new blood vessels (called angiogenesis) to supply blood carrying nutrients is critical in cancer growth, Dr. Rich's team studied if the formation of tumors by stem cell-like glioma cells could be due to increased angiogenesis. Angiogenesis is often stimulated by a key growth factor called VEGF. Rich and colleagues found that stem cell-like glioma cells enhanced the angiogenesis of gliomas through increased levels of VEGF.
Using an antibody to mark the cancer stem cells in gliomas obtained from patient specimens, the Rich laboratory determined that between three-to-five percent of tumor cells were of the stem cell-like variety. They found that these stem cell-like glioma cancer cells expressed much higher levels of VEGF and formed more tumors with more blood vessels than glioma cells that did not have stem cell characteristics. Adding an antibody (bevacizumab, also known by the trade name Avastin) that blocks VEGF activity blocked new blood vessel formation and prevented tumor growth. The researchers suggest that the stem cell-like glioma cells, because of their support of angiogenesis, could hold an important target to suppressing the growth of brain cancer.
"VEGF antibodies may be effective as cancer therapies when combined with chemotherapy by improving delivery directly and specifically to stem cell-like tumor cells," said Dr. Rich. "Targeting VEGF in this way would not kill cancer cells directly, but instead would block the actions of adjacent cells that support the growth of their blood supply."
Dr. Rich's lab studies the complex relationships between cell signaling pathways and the development of cancer, especially in the nervous system. The lab is investigating a number of molecular targets that contribute to cancer growth and malignancy.
"Too often, brain tumor patients have been told there is no hope. Our overall objective is to give brain tumor patients that hope, while we do not expect to achieve instant victories in the near future," said Dr. Rich.
Warren Froelich | EurekAlert!
Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg
Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy